This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marcus, R. Articles by Stock, J. L. Search for Related Content PubMed PubMed Citation Articles by Marcus, R. Articles by Stock, J. L.

Antiresorptive Treatment of Postmenopausal Osteoporosis: Comparison of Study Designs and Outcomes in Large Clinical Trials with Fracture as an Endpoint

Department of Medicine, Stanford University School of Medicine, and the Musculoskeletal Research Laboratory, Geriatric Research, Education, and Clinical Center, Veterans’ Affairs Medical Center (R.M.), Palo Alto, California 94304; and Lilly Research Laboratories, Eli Lilly and Company (M.W., H.H.III, J.L.S.), Indianapolis, Indiana 46285

Correspondence: Address all correspondence and requests for reprints to: Robert Marcus, M.D., Professor of Medicine, Stanford University, Geriatric Research, Education, and Clinical Center 182-B, Veterans’ Affairs Medical Center, 3801 Miranda Avenue, Palo Alto, California 94304. E-mail: marcuse{at}Stanford.edu

Antiresorptive treatments for postmenopausal osteoporosis have been studied extensively, but due to the volume of published data and lack of head-to-head trials, it is difficult to evaluate and compare their fracture reduction efficacy. The objective of this review is to summarize the results from clinical trials that have fracture as an endpoint and to discuss the factors in study design and populations that can affect the interpretation of the results. Although there are numerous observational studies suggesting that estrogen and hormone replacement therapies may reduce the risk of vertebral and nonvertebral fractures, there is no large, prospective, randomized, placebo-controlled, double-blind clinical trial demonstrating fracture efficacy. The effects of raloxifene, alendronate, risedronate, and salmon calcitonin on increasing bone mineral density (BMD) and decreasing fracture risk have been shown in randomized, placebo-controlled, double-blind clinical trials of postmenopausal women with osteoporosis. Although the increases in lumbar spine BMD vary greatly in these trials, the decrease in relative risk of vertebral fractures is similar among therapies. However, nonvertebral fracture efficacy has not been consistently demonstrated. Combined administration of two antiresorptive therapies results in greater BMD increases, but the effects on fracture risk are unknown. Direct comparisons of clinical trial results should be considered carefully, given the differences in study design and populations. Differences in study design that may influence the efficacy of fracture risk reduction include calcium and vitamin D supplementation, primary fracture endpoints, definition of vertebral deformity or fracture, discontinuation rates, and statistical power. Factors in the study population that may influence fracture efficacy include the age of the population and the proportion of subjects with prevalent fractures. The use of surrogate endpoints such as BMD to predict fracture risk should be approached with caution, as the relationship between BMD changes and fracture risk reduction with antiresorptive therapies is uncertain. Consideration of these results from clinical trials can contribute to clinical judgment in selecting the best treatment option for postmenopausal osteoporosis.

This article has been cited by other articles:

				K. A. Hegge, A. S. Fornoff, S. L. Gutierres, and S. L. Haack New Therapies for Osteoporosis Journal of Pharmacy Practice, February 1, 2009; 22(1): 53 - 64. [Abstract] [PDF]

				L. Tauchmanova, A. Colao, G. Lombardi, B. Rotoli, and C. Selleri REVIEW: Bone Loss and Its Management in Long-Term Survivors from Allogeneic Stem Cell Transplantation J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4536 - 4545. [Abstract] [Full Text] [PDF]

				F. Jakob, F. Marin, E. Martin-Mola, D. Torgerson, P. Fardellone, S. Adami, N.C. Thalassinos, D. Sykes, J. Melo-Gomes, C. Chinn, et al. Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO) QJM, August 1, 2006; 99(8): 531 - 543. [Abstract] [Full Text] [PDF]

				K. F. Mauck and B. L. Clarke Diagnosis, Screening, Prevention, and Treatment of Osteoporosis Mayo Clin. Proc., May 1, 2006; 81(5): 662 - 672. [Abstract] [Full Text] [PDF]

				L. Tauchmanova, P. Ricci, B. Serio, G. Lombardi, A. Colao, B. Rotoli, and C. Selleri Short-Term Zoledronic Acid Treatment Increases Bone Mineral Density and Marrow Clonogenic Fibroblast Progenitors after Allogeneic Stem Cell Transplantation J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 627 - 634. [Abstract] [Full Text] [PDF]

				G. J. Strewler Long-Term Bisphosphonates for Osteoporosis: An Introduction IBMS BoneKEy, January 1, 2005; 2(1): 6 - 9. [Full Text] [PDF]

				K. L. Becker, E. S. Nylen, J. C. White, B. Muller, and R. H. Snider Jr. Procalcitonin and the Calcitonin Gene Family of Peptides in Inflammation, Infection, and Sepsis: A Journey from Calcitonin Back to Its Precursors J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1512 - 1525. [Full Text] [PDF]

				M. Doren, J.-A. Nilsson, and O. Johnell Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis Hum. Reprod., August 1, 2003; 18(8): 1737 - 1746. [Abstract] [Full Text] [PDF]